Zacks Investment Research downgraded shares of PROTHENA CP PLC (PRTA) from OUTPERFORM to NEUTRAL on September 03, 2014, with a target price of $24.20.
Prothena Corporation plc is a biotechnology company focused on the discovery and development of therapeutic monoclonal antibodies for disease-causing proteins. The Company is developing the following programs: NEOD001 for Amyloidosis, NEOD002 for Parkinson's disease, MCAM for Inflammatory disease and Metastatic Cancer and Tau for Alzheimer's disease. Prothena Corporation plc is headquartered in Dublin, Ireland.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on PROTHENA CP PLC (PRTA),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment